A股申购 | 爱得科技(920180.BJ)开启申购 主要从事以骨科耗材为主的医疗器械的研发、生产与销售

Core Viewpoint - Aide Technology (920180.BJ) has initiated its subscription on February 2, with an issue price of 7.67 yuan per share and a subscription limit of 1.3288 million shares, operating under a market P/E ratio of 14.98 times, and is listed on the Beijing Stock Exchange, with Debon Securities as its sponsor [1]. Company Overview - Aide Technology specializes in the research, production, and sales of medical devices, primarily focusing on orthopedic consumables, including spinal, trauma, and sports medicine products, as well as wound healing products [1][2]. - The company aims to become a leading provider of comprehensive orthopedic surgical solutions in China, guided by clinical needs in orthopedics [1][2]. Market Position - The company has been deeply involved in the orthopedic medical device industry for over a decade, focusing on integrated surgical solutions based on clinical needs [2]. - As of the signing of the prospectus, Aide Technology has 132 product registrations or certifications, including 62 Class I, 34 Class II, and 35 Class III products, along with one imported medical device [2]. Financial Performance - In 2022, 2023, 2024, and the first half of 2025, the company reported revenues of approximately 286 million yuan, 262 million yuan, 275 million yuan, and 149 million yuan, respectively, with net profits of approximately 93.39 million yuan, 63.57 million yuan, 66.79 million yuan, and 38.22 million yuan [3]. - The total assets as of June 30, 2025, are approximately 652.06 million yuan, with total equity of about 543.81 million yuan [4]. - The company’s gross profit margin has shown slight fluctuations, recorded at 58.89% in the first half of 2025, compared to 62.45% in 2022 [4]. Investment Projects - The funds raised will be allocated to several projects, including: - Phase I orthopedic consumables expansion project: total investment of 12.83 million yuan, with 10.25 million yuan from raised funds - R&D center construction project: total investment of 5.27 million yuan, fully funded by raised funds - Marketing network construction project: total investment of 4.19 million yuan, fully funded by raised funds - The total investment for these projects amounts to 22.28 million yuan, with 19.70 million yuan from the raised funds [3]. Key Metrics - The company’s weighted average return on equity was 7.28% for the first half of 2025, down from 23.22% in 2022 [5]. - Basic and diluted earnings per share were both 0.43 yuan for the first half of 2025, compared to 1.04 yuan in 2022 [5]. - R&D expenditure as a percentage of revenue was 6.79% in the first half of 2025, an increase from 5.91% in 2022 [5].